n an article entitled, “The innovative evolution of cancer gene and cellular therapies,” published online February 1, 2013, the lead author P. Lam along with six more authors affiliated seven research organizations provide
an overview of the latest developments in cancer gene therapy. The therapy in which biologics and biosimilars are used
has been acclaimed by large pharmaceutical companies such as Amgen and its subsidiary Biovex to pave the way for efficacious treatments of pernicious cancers such as breast, stomach, renal cancers where survival rate has not hitherto been substantial. Now that a breakthrough by the use of biologic and biosimilar has been made, the day is not very far away when cancer patients can look forward to the kind of treatment which can bring about complete remission of this scourge taking a toll of human lives by millions every year.